Pathogenics retains the exclusive worldwide rights to NCT for all indications other than ophthalmic (eye related) applications.
Acuity is paying Pathogenics an up-front licensing fee and minimum annual license fees, as well as milestones and royalties. Further details of the agreement were not disclosed.
Acuity gains worldwide development and commercialization rights to NCT for the treatment of ophthalmic diseases and infections, such as viral conjunctivitis, bacterial conjunctivitis and herpetic keratitis.
Acuity is responsible for clinical development, regulatory activities and commercialization of this compound in ophthalmic indications.
“We are very excited about the broad-spectrum potential of NCT to safely treat ophthalmic diseases and infections,” commented Fred Zotos, president and CEO of Pathogenics. “We have every confidence that Acuity Pharmaceuticals will prove itself to be an extremely capable corporate partner in developing NCT as an ophthalmic treatment.”